

1 **Notable transmitted HIV drug resistance among people who** 2 **inject drugs in Pakistan**

3

4 Stephanie Melnychuk^{1,2}, Laura H. Thompson³, Chris Archibald³, James F. Blanchard¹, Faran
5 Emmanuel¹, Tahira Reza⁴, Nosheen Dar⁵, Paul Sandstrom², Souradet Y. Shaw¹, Marissa L.
6 Becker¹, François Cholette^{2,6*}

7

8 ¹Institute for Global Public Health, Department of Community Health Sciences, University of
9 Manitoba, Winnipeg, Canada

10 ²National Sexually Transmitted and Blood Borne Infection Laboratory, National Microbiology
11 Laboratory at the J.C. Wilt Infectious Diseases Research Centre, Public Health Agency of
12 Canada, Winnipeg, Canada

13 ³Sexually Transmitted and Bloodborne Infections Surveillance Division, Centre for
14 Communicable Diseases and Infection Control, Public Health Agency of Canada, Ottawa,
15 Ontario, Canada

16 ⁴Centre for Global Public Health, Pakistan, Chak Shahzad, Islamabad, Pakistan

17 ⁵Canada-Pakistan HIV/AIDS Surveillance Project, Islamabad, Pakistan

18 ⁶Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine,
19 University of Manitoba, Winnipeg, Canada.

20

21 *Corresponding author:

22 Email: francois.cholette@phac-aspc.gc.ca (FC)

23 Abstract

24 Transmission of drug-resistant HIV strains to treatment-naïve patients can compromise
25 antiretroviral therapy (ART) effectiveness and lead to treatment failure. In Pakistan, transmitted
26 HIV drug resistance among people who inject drugs (PWID) is fuelled by a lack of ART, poor
27 drug adherence, and unsafe injection practices, resulting in efficient transmission in large
28 injecting networks. A cross-sectional study was conducted among PWID recruited in the
29 Pakistani cities of Karachi, Larkana, Peshawar, Quetta and Hyderabad (August 2014 to January
30 2015). A portion of the HIV *pol* gene was amplified from HIV-reactive dried blood spot
31 specimens ($n=282/367$) and sequenced using an in-house Sanger sequencing assay for HIV drug
32 resistance mutation genotyping. Drug resistance mutations (DRMs) were identified using the
33 Stanford University HIV Drug Resistance Database HIVdb algorithm
34 (<https://hivdb.stanford.edu/hivdb>). Overall, HIV subtype A1 was dominant (78.0%; $n=220$),
35 followed by CRF02_AG (15.6%; $n=44$), CRF35_AD (2.5% $n=7$), recombinants (3.5%; $n=10$),
36 and subtype C (0.4% $n=1$). DRM analysis identified over half (63.8%) of participants harbored at
37 least one DRM, of which 28.9% reported using help from a professional injector. Nearly all
38 (99.4%) participants were not actively receiving ART because most (88.7%) had never
39 undergone HIV testing and were unaware of their status. Findings suggest significant transmitted
40 HIV drug resistance present among PWID, exacerbated by unsafe injection practices,
41 particularly professional injection. Low testing rates signal a need for more comprehensive
42 testing programs to improve HIV status awareness and ART coverage in Pakistan. Given most
43 treatment-naïve participants had evidence of drug resistance, drug resistance genotyping prior to
44 ART initiation might aid in ensuring effective treatment to prevent transmission of resistant HIV
45 strains.

47 **Introduction**

48 In Pakistan, HIV prevalence is estimated to be 0.1% in the general population, but is
49 known to be much higher among people who inject drugs (PWID), with estimates as high as
50 40% of PWID in the country living with HIV (1,2). This considerable burden is attributable to
51 the marginalization of PWID due to contextual factors, including illiteracy, poverty,
52 homelessness, and criminalization (3–5), which constrain access to both harm reduction
53 programs and antiretroviral therapy (ART) (6). Further, the requirement of individuals actively
54 injecting drugs to undergo a two-week drug detoxification prior to ART initiation (7) and lack of
55 a national opioid substitution therapy program in Pakistan presents structural barriers which
56 might contribute to higher rates of HIV transmission among PWID overall, hindering effective
57 HIV management and posing challenges to overall HIV epidemic control efforts in the country
58 (8–10).

59 PWID undergoing ART have increased vulnerability to treatment interruptions due to a
60 lack of social support and stable housing, mental health comorbidities, and effects of stigma and
61 discrimination (9,11,12). Suboptimal therapy and non-adherence to ART facilitates the selection
62 of viral strains harboring drug resistance mutations (DRMs) (13) which can be transmitted to
63 ART-naïve individuals, constituting what is defined as transmitted drug resistance (14).
64 Transmitted drug resistance poses challenges to virological suppression and achieving
65 undetectable viral loads in ART-naïve patients harboring DRMS (15,16), with studies
66 documenting high risk of failing first-line therapy in ART-naïve patients harboring DRMs (17–
67 19).

68 The disproportionate burden of transmitted drug resistance facing PWID may be fuelled
69 by the rapid and efficient transmission of drug-resistant HIV strains in large, interconnected

70 injecting networks with high frequency of sharing injecting equipment (20,21) in certain
71 contexts, including Pakistan (22). High daily injection frequency (23), sharing syringes and other
72 drug use paraphernalia (22), injection of shared blood-drug mixtures (24), and help from
73 professional injectors (3), have been previously identified as risk factors among PWID in
74 Pakistan.

75 Few studies have looked at baseline HIV DRMs among people living with HIV in
76 Pakistan (5,25–27), with even fewer looking specifically at PWID. Knowledge of DRMs is
77 essential for guiding ART selection, as ARTs are currently prescribed in Pakistan without
78 baseline drug resistance genotyping (26). This increases the risk of ineffective treatment. Using
79 data from a cross-sectional survey conducted in 2014 (28), we sought to assess HIV drug
80 resistance in PWID across five major cities in Pakistan.

81

82 **Material and Methods**

83 **Study setting**

84 For this cross-sectional study, PWID were recruited from August 2014 to January 2015
85 across five major cities in Pakistan. To ensure accurate reflection the study population, a detailed
86 mapping of size, geography, and operation typology of the PWID population was conducted
87 prior to the survey as described previously elsewhere (29).

88 Following informed consent, participants were interviewed to collect information
89 pertaining to sociodemographics, drug use practices, and utilization of HIV prevention and care
90 services, as well as a dried blood spot (DBS) specimen.

91 **HIV serology and *pol* sequencing**

92 DBS were shipped to the National Sexually Transmitted and Blood Borne Infection
93 Laboratory (Public Health Agency of Canada, Winnipeg, Canada). Serological testing using the
94 AVIOQ HIV Microelisa System (Avioq Inc., Durham, NC) was performed according to the
95 manufacturer's instructions. HIV drug resistance mutation genotyping was attempted on all HIV-
96 reactive DBS.

97 A routine, in-house HIV drug resistance mutation genotyping assay was used to amplify
98 and sequence a portion of the *pol* open reading frame (nt 2,074–3,334 on HXB2, [K03455](#)) from
99 DBS as previously described (28). Sequence analysis and contig assembly was performed using
100 RECall (30). HIV *pol* sequences are available via a public repository (i.e. NCBI) under accession
101 numbers [MN887780-MN888069](#).

102 **HIV subtyping and drug resistance mutation analysis**

103 PWID HIV *pol* sequences were aligned, visually inspected, and manually edited in
104 MEGA v7 (31) as required. Subtyping was carried out using REGA HIV automated subtyping
105 tool v3 (32) and COMET (33), with SCUEAL (34) used as a tiebreaker for discordant results.

106 The Stanford HIV Drug Resistance Database program v9.4.1 (<https://hivdb.stanford.edu>)
107 (35) was used to assess for mutations in the HIV *pol* gene associated with resistance to protease
108 and reverse transcriptase inhibitors. Sequences containing one or more DRMs were considered
109 drug-resistant (DR). Any DRMs identified for which no clinical implications were found in the
110 literature were discarded.

111 **Statistical analyses**

112 Descriptive statistics were calculated for sociodemographic and behavioral information.
113 Pearson's chi-square test was applied between DR classification and predictor variables using
114 SciPy (36), where $P < 0.050$ was used to define statistically significant associations.

115 **Ethics**

116 Ethics board approval was obtained from the Health Research Ethics Board at the
117 University of Manitoba [HS15691(H2012:294)] and BRIDGE Consultants Foundation, Pakistan.
118 Informed consent was obtained verbally from study participants and documented by a member of
119 the data collection team for the behavioural survey and biological sampling components of this
120 study. Verbal consent was chosen due to varying levels of literacy among study participants and
121 as an additional measure of protecting their identities.

122

123 **Results**

124 **Study population and sequence dataset**

125 A total of 1,453 PWID consented to participate in the study from Karachi ($n = 300$),
126 Larkana ($n = 300$), Peshawar ($n = 253$), Quetta ($n = 300$) and Hyderabad ($n = 300$). All
127 participants consented to providing a DBS sample. Serological testing identified 367 (25.5%)
128 PWID living with HIV.

129 Of the HIV-reactive DBS specimens, 287 *pol* sequences (79.0%) were amplified –
130 corresponding to 80% of HIV-reactive DBS from each city except Hyderabad, where
131 amplification success was closer to 70%. In accordance with WHO HIV drug resistance criteria
132 (37), five sequences containing premature stop codons were removed from subsequent analysis.
133 Of 282 *pol* sequences, 109 (38.7%) were from Karachi, 90 (31.9%) from Peshawar, 39 (13.8%)
134 from Hyderabad, 25 (8.9%) from Larkana, and 19 (6.7%) from Quetta. Most sequences were
135 classified as subtype A1 ($n=220$, 78.0%), followed by CRF02_AG ($n=44$, 15.6%), CRF35_AD
136 ($n=7$, 2.5%), recombinants ($n=10$, 3.5%), and subtype C ($n=1$, 0.4%).

137 Sociodemographic characteristics

138 Sociodemographic and behavioral information of PWID for whom HIV sequences were
139 obtained is presented in Table 1. All participants were male. Of 282 sequences analyzed, 180
140 (63.8%) were considered DR.

141 Statistically significant predictors of DR classification were city of residence and age
142 ($P<0.05$) (Table 1). Years injecting, daily injection frequency, injection method, and ART status
143 were not significantly associated with DR. Prevalence of DR ranged from 33.3% to 94.7%
144 among participants when stratified by city. Of those with DR sequences, the highest proportion
145 (39.4%) were between 25-29 years of age. Using help from a professional injector was slightly
146 higher in DR participants (28.9%). Of participants who had undergone HIV testing and were
147 aware of their positive status ($n=32$, 11.3%), one (3.1%) was actively receiving ART.

148

149 **Table 1. Sociodemographic and behavioral characteristics of people who inject drugs in**
150 **Pakistan stratified according to presence of drug resistance mutations in HIV sequences.**

Variable	DR (≥ 1 DRM) ($N=180$)	Non-DR ($N=102$)	P^*
City, n			<0.001
Hyderabad	35	4	
Karachi	75	34	
Larkana	22	3	
Peshawar	30	60	
Quetta	18	1	
Age, n (%)			0.010
<24	43 (23.9)	40 (39.2)	
25-29	71 (39.4)	26 (25.5)	
≥ 30	66 (36.7)	36 (35.3)	
Years injecting drugs, n (%) ^a			0.200
<2	32 (17.8)	21 (20.6)	

2-4	64 (35.6)	44 (43.1)	
≥5	84 (46.7)	36 (35.3)	
Times injecting the previous day, <i>n</i> (%)			0.130
0	45 (25.0)	15 (14.7)	
1	74 (41.1)	48 (47.1)	
≥2	61 (31.7)	39 (37.3)	
Injection method at last injection, <i>n</i> (%)			0.200
Without help	104 (57.8)	70 (68.6)	
Uses help, but not from a professional injector	24 (13.3)	10 (9.8)	
Uses help from a professional injector	52 (28.9)	22 (21.6)	
Current ART treatment status, <i>n</i> (%)			0.720
No	19 (10.6)	12 (11.8)	
Yes	1 (0.6)	0 (0.0)	
Not specified ^b	160 (88.9)	90 (88.2)	

151 Table 1 legend:

152 **P*-value based on Pearson chi-square test.

153 ^aAmong respondents does not add to 100%.

154 ^bLow response rate for HIV treatment is because most participants had never undergone HIV testing and
155 did not respond to questions regarding ART.

156

157 **Analysis of HIV drug resistance analysis**

158 HIV mutations associated with drug resistance are summarized in Table 2. Of 282
159 analysed HIV *pol* sequences, 13 DRMs were identified among the 180 DR participants: two
160 protease inhibitor (PI), two nucleoside RT inhibitor (NRTI), and nine non-nucleoside RT
161 inhibitor (NNRTI) mutations (Table 2).

162

163 **Table 2. Drug-resistance mutations in HIV sequences from people who inject drugs across**
 164 **several Pakistani cities.**

		All cities (N=282)	Hyderabad (N=39)	Karachi (N=109)	Larkana (N=25)	Peshawar (N=90)	Quetta (N=19)
DRMs ^a , n (%)							
PIs	M46I*	1 (0.4)	0 (0.0)	1 (0.9)	0 (0.0)	0 (0.0)	0 (0.0)
	L10F	1 (0.4)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.1)	0 (0.0)
NRTIs	K219R*	2 (0.7)	0 (0.0)	2 (1.8)	0 (0.0)	0 (0.0)	0 (0.0)
	S68G	1 (0.4)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.1)	0 (0.0)
NNRTIs	K101E*	2 (0.7)	0 (0.0)	0 (0.0)	0 (0.0)	2 (2.2)	0 (0.0)
	K103N*	3 (1.1)	0 (0.0)	0 (0.0)	0 (0.0)	2 (2.2)	1 (5.3)
	V106I	1 (0.4)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.1)	0 (0.0)
	E138A	164 (58.2)	34 (87.2)	70 (64.2)	22 (88.0)	21 (23.3)	17 (89.5)
	E138APQ	1 (0.4)	0 (0.0)	1 (0.9)	0 (0.0)	0 (0.0)	0 (0.0)
	V179D	2 (0.7)	0 (0.0)	0 (0.0)	1 (4.0)	0 (0.0)	1 (5.3)
	V179T	11 (3.9)	1 (2.6)	5 (4.6)	0 (0.0)	4 (4.4)	1 (5.3)
	V179IT	2 (0.7)	0 (0.0)	1 (0.9)	0 (0.0)	0 (0.0)	1 (5.3)
	Y188H*	1 (0.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (5.3)
Genotype, n (%)							
A1		220 (78.0)	35 (89.7)	73 (67.0)	22 (88.0)	73 (81.1)	17 (89.5)
CRF 02_AG		44 (15.6)	1 (2.6)	29 (26.6)	3 (12.0)	10 (11.1)	1 (5.3)
REC ^b		10 (3.5)	2 (5.1)	1 (0.9)	0 (0.0)	7 (7.8)	0 (0.0)
CRF 35_AD		7 (2.5)	1 (2.6)	5 (4.6)	0 (0.0)	0 (0.0)	1 (5.3)
C		1 (0.4)	0 (0.0)	1 (0.9)	0 (0.0)	0 (0.0)	0 (0.0)

165 Table 2 legend:

166 *DRM belongs to WHO 2009 list of mutations for surveillance of HIV drug resistance (38).
167 ^aPIs: M46I is associated with low- to intermediate-level resistance to indinavir, nelfinavir, fosamprenavir,
168 lopinavir, saquinavir, and atazanavir (39); and L10F is an accessory DRM associated with reduced
169 lopinavir and darunavir susceptibility (40). NRTIs: K219R confers resistance to azidothymidine (41,42);
170 and S68G is associated with K65R mutants to improve viral replication (43). NNRTIs: K101E confers
171 highly-reduced susceptibility to nevirapine and decreases efavirenz, etravirine, and rilpivirine
172 susceptibility (44); K103N is associated with resistance to nevirapine and efavirenz (45,46); V106I
173 confers potential low-level resistance to doravirine, etravirine, nevirapine, and rilpivirine (47); E138A and
174 E138Q confer reduced susceptibility to etravirine and reduced, potentially full, susceptibility to rilpivirine
175 (48,49); V179D is associated with low-level resistance to efavirenz, nevirapine, etravirine, and rilpivirine
176 (50); V179T has been reported with reduced susceptibility to etravirine in the presence of other DRMs
177 (51); V179I is associated with resistance to etravirine and rilpivirine (52); and Y188H has been reported
178 to confer resistance to nevirapine and efavirenz (53).
179 ^b“REC” indicates sequences classified as recombinants.

180
181 DRM E138A was the most common mutation across all cities (58.2%), with almost all
182 sequences from Hyderabad, Larkana, and Quetta containing this mutation (87.2%, 88.0%, and
183 89.5%, respectively). Karachi sequences had the only reports of DRMs M46I, K219R, and
184 V179T. Despite Peshawar having the smallest percentage (33.3%) of sequences containing any
185 DRMs, these sequences had the most diversity, containing 7 of the 13 DRMs in our analysis,
186 including the only observances of L10F, S68G, K101E, and V106I. The mutation K103N was
187 only reported in two sequences from Peshawar and one sequence from Quetta.

188

189 **Discussion**

190 Here, we present HIV drug resistance mutations from a cross-sectional survey conducted
191 in 2014 among PWID from five cities in Pakistan. Our analysis demonstrated a high prevalence
192 of DRMs associated with NNRTI resistance. The vast majority of participant sequences from
193 Hyderabad (89.7%), Karachi (68.8%), Larkana (88.0%), and Quetta (94.7%) contained at least
194 one DRM. Given that only one (0.6%) study participant reported actively receiving ART,
195 observing DRMs in high frequency among participants suggests significant HIV transmitted
196 drug resistance present among PWID in Pakistan.

197 Over half (58.2%) of PWID in our study harbored E138A, conferring low-level resistance
198 to the NNRTIs etravirine and rilpivirine (48,49). Other studies have observed E138A among
199 people living with HIV in Pakistan, reporting varying prevalence in ART-experienced (13-78%)
200 and ART-naïve (8-39%) cohorts (5,27). Perhaps more concerning are the DRMs observed in low
201 prevalence conferring resistance to efavirenz— namely K101E (44), K103N (45,46), V179D (50),
202 and V188H (53). Pakistan’s first-line ART regimen for adults is currently tenofovir and
203 lamivudine with dolutegravir (54), although efavirenz was formerly used in first-line regimens at
204 the time of our study (55) and is currently suggested for use in alternate regimens. Our results
205 suggest first-line regimens would be effective treatment for most PWID living with HIV who
206 participated in our study, although this might not be true for previous regimens. While Pakistan
207 has second-line regimens, these drugs are more prone to shortages compared with first-line
208 regimens (56), posing challenges to HIV treatment in individuals harboring resistance to efavirenz
209 prior to the change to dolutegravir in 2019 (57) and enabling transmission of drug-resistant
210 strains.

211 We observed city of residence and age to be significantly associated with DR
212 classification. Participants with DR sequences reported slightly higher prevalence of help from a

213 professional injector compared to non-DR sequences (28.9% versus 21.6% respectively), and
214 while method at last injection was not significantly associated to DR, we did not stratify the
215 analysis by city and injection method to determine its significance for each study city.
216 Professional injectors (or street doctor) are PWID themselves who reuse the same injecting
217 equipment to inject several clients – often younger and inexperienced PWID – daily, for a fee
218 (58–60). This fee can be something known as “scale”, a blood-drug mixture collected by the
219 professional injector by double-pumping the syringe, which is then sold to other PWID for less
220 than the regular drug (22,28,61), allowing for efficient transmission of drug-resistant HIV. Using
221 help from professional injectors has previously been reported to be more prevalent in Karachi
222 (53.7%) compared to Peshawar (25.2%) and Quetta (19.6%) (59). Differences in DRM
223 prevalence among cities might also be partially explained by varying rates of heroin injection,
224 observed to be high in Karachi and Quetta (96.9% and 81.1% respectively) (59). Heroin has been
225 associated with high-risk injection practices, such as needle sharing and “jerking”, where heroin
226 is mixed with blood and shared amongst injectors (6), facilitating transmission of resistant strains
227 among PWID.

228 In this study, we report the spread of drug-resistant HIV is likely being fuelled by the
229 lack of ART coverage among PWID participants, permitting high viral loads which enable
230 efficient HIV transmission. Our findings stress the lack of ART coverage among PWID in
231 Pakistan, known to still be an ongoing issue and major obstacle to HIV treatment in the country.
232 The low ART coverage observed in our study is likely due in part to the lack of participants’
233 awareness that they are living with HIV overall, as we observed nearly all (88.7%) PWID
234 participants to have never undergone HIV testing. Awareness of HIV status among people in
235 Pakistan is known to be low (21%), with people living with HIV actively receiving ART being

236 even lower (12%) (62). Moreover, it is well established that PWID face barriers to ART access,
237 specifically identifying Pakistan’s lack of national opioid substitution therapy program as a key
238 intervention to HIV prevention that remains illegal (8,11).

239

240 **Conclusions**

241 By sequencing, genotyping, and assessing for HIV drug resistance, we have been able to
242 identify the circulating HIV strains and the level of drug resistance among PWID in Pakistan.
243 Overall, our study indicates that few DRMs are found amongst PWID in Pakistan conferring
244 low-level resistance to etravirine, rilpivirine, and efavirenz. While our results suggest the
245 majority of PWID in our study would be susceptible to current first-line ART regimes, perhaps
246 more concerning is their lack of awareness of HIV-positive status and extremely limited access
247 to treatment. These findings highlight a need for more comprehensive testing programs among
248 PWID to increase HIV status awareness and drug resistance genotyping prior to ART initiation
249 to ensure effective treatment of resistant HIV strains.

250

251 **Acknowledgements**

252 We thank the surveillance team for their efforts in mapping, data collection, specimen collection
253 and data entry. We also thank the participants who took part in the surveys for their time and
254 participation. We thank Kiana Kadivar (National Sexually Transmitted and Blood Borne
255 Infection Laboratory) for her initial assistance with coordinating serological testing.

256 **References**

- 257 1. UNAIDs. Country Progress Report - Pakistan [Internet]. 2020 [cited 2023 Oct 29].
258 Available from:
259 [https://www.unaids.org/sites/default/files/country/documents/PAK_2020_countryreport.p](https://www.unaids.org/sites/default/files/country/documents/PAK_2020_countryreport.pdf)
260 [df](https://www.unaids.org/sites/default/files/country/documents/PAK_2020_countryreport.pdf)
- 261 2. UNAIDs. Country Factsheets: Pakistan [Internet]. 2022 [cited 2023 Aug 13]. Available
262 from: <https://www.unaids.org/en/regionscountries/countries/pakistan>
- 263 3. Lim AG, Trickey A, Thompson LH, Emmanuel F, Reza TE, Reynolds R, et al.
264 Elucidating Drivers for Variations in the Explosive Human Immunodeficiency Virus
265 Epidemic among People Who Inject Drugs in Pakistan. *Open Forum Infect Dis*.
266 2021;8(9).
- 267 4. Salman Y, Shaeen SK, Butt MS, Vohra LI, Hashmi T. HIV in Pakistan: Challenges,
268 efforts and recommendations. *Ann Med Surg*. 2022;84.
- 269 5. Shah S, Xing H, Altaf A, Chen B, Liao L, Jia Y, et al. Antiretroviral drug resistance
270 mutations among treated and treatment-naïve patients in Pakistan: Diversity of the HIV
271 type 1 pol gene in Pakistan. *AIDS Res Hum Retroviruses*. 2011;27(12).
- 272 6. Capelastegui F, Trickey A, Thompson LH, Reza T, Emmanuel F, Cholette F, et al. Risk
273 factors of HIV and variation in access to clean needles among people who inject drugs in
274 Pakistan. *Pathog Glob Health*. 2023;117(8).
- 275 7. Nai Zindagi Trust. ART adherence unit: A therapeutic community facility that aims to
276 improve HIV treatment outcomes for people who inject drugs in Pakistan [Internet]. 2016
277 [cited 2023 Nov 2]. Available from: <https://www.naizindagi.org/treatment-and-adherence/>

- 278 8. Bergenstrom A, Achakzai B, Furqan S, ul Haq M, Khan R, Saba M. Drug-related HIV
279 epidemic in Pakistan: A review of current situation and response and the way forward
280 beyond 2015. *Harm Reduct J*. 2015;12(1).
- 281 9. Malta M, Magnanini MMF, Strathdee SA, Bastos FI. Adherence to antiretroviral therapy
282 among HIV-infected drug users: A meta-analysis. *AIDS Behav*. 2010;14(4).
- 283 10. Nosyk B, Min JE, Colley G, Lima VD, Yip B, Milloy MJS, et al. The causal effect of
284 opioid substitution treatment on HAART medication refill adherence. *AIDS*. 2015;29(8).
- 285 11. Iversen J, Qureshi S ul H, Zafar M, Busz M, Maher L. Adherence to antiretroviral therapy
286 among HIV positive men who inject drugs in Pakistan. *Int J Drug Policy*. 2021;96.
- 287 12. Daud MY ousuf, Qazi RA ziz, Bashir N. Anti-retroviral drugs compliance in intravenous
288 and non intravenous drug abusers. *J Ayub Med Coll Abbottabad*. 2014;26(4).
- 289 13. Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE. Association between
290 Adherence to Antiretroviral Therapy and Human Immunodeficiency Virus Drug
291 Resistance. *Clin Infec Dis*. 2003;37(8).
- 292 14. WHO. HIV drug resistance report 2017 [Internet]. Geneva; 2017 [cited 2023 Dec 7].
293 Available from: [https://iris.who.int/bitstream/handle/10665/255896/9789241512831-](https://iris.who.int/bitstream/handle/10665/255896/9789241512831-eng.pdf)
294 [eng.pdf](https://iris.who.int/bitstream/handle/10665/255896/9789241512831-eng.pdf)
- 295 15. McCluskey SM, Siedner MJ, Marconi VC. Management of Virologic Failure and HIV
296 Drug Resistance. *Infect Dis Clin North Am*. 2019;33(3).
- 297 16. van Zyl G, Bale MJ, Kearney MF. HIV evolution and diversity in ART-treated patients.
298 *Retrovirology*. 2018;15(1).
- 299 17. Ávila-Ríos S, García-Morales C, Matías-Florentino M, Romero-Mora KA, Tapia-Trejo D,
300 Quiroz-Morales VS, et al. Pretreatment HIV-drug resistance in Mexico and its impact on

- 301 the effectiveness of first-line antiretroviral therapy: a nationally representative 2015 WHO
302 survey. *Lancet HIV*. 2016;3(12).
- 303 18. Gupta RK, Gregson J, Parkin N, Haile-Selassie H, Tanuri A, Andrade Forero L, et al.
304 HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in
305 low-income and middle-income countries: a systematic review and meta-regression
306 analysis. *Lancet Infect Dis*. 2018;18(3).
- 307 19. Hamers RL, Schuurman R, Sigaloff KCE, Wallis CL, Kityo C, Siwale M, et al. Effect of
308 pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance
309 outcomes of first-line antiretroviral treatment in sub-Saharan Africa: A multicentre cohort
310 study. *Lancet Infect Dis*. 2012;12(4).
- 311 20. Des Jarlais DC, Kerr T, Carrieri P, Feelemyer J, Arasteh K. HIV infection among persons
312 who inject drugs: Ending old epidemics and addressing new outbreaks. *AIDS*. 2016;30(6).
- 313 21. Pham QD, Wilson DP, Law MG, Kelleher AD, Zhang L. Global burden of transmitted
314 HIV drug resistance and HIV-exposure categories: A systematic review and meta-
315 analysis. *AIDS*. 2014;28(18).
- 316 22. Emmanuel F, Archibald C, Razaque A, Sandstrom P. Factors Associated With an
317 Explosive HIV Epidemic Among Injecting Drug Users in Sargodha, Pakistan. *JAIDS*.
318 2009 May;51(1):85–90.
- 319 23. Samo RN, Altaf A, Agha A, Pasha O, Rozi S, Memon A, et al. High HIV incidence
320 among persons who inject drugs in Pakistan: Greater risk with needle sharing and
321 injecting frequently among the homeless. *PLoS One*. 2013;8(12).

- 322 24. Strathdee SA, Hallett TB, Bobrova N, Rhodes T, Booth R, Abdool R, et al. HIV and risk
323 environment for injecting drug users: The past, present, and future. *Lancet*.
324 2010;376(9737).
- 325 25. Khan S, Zahid M, Qureshi MA, Mughal MN, Ujjan ID. HIV-1 genetic diversity,
326 geographical linkages and antiretroviral drug resistance among individuals from Pakistan.
327 *Arch Virol*. 2018;163(1).
- 328 26. Siddiqui D, Badar U, Javaid M, Farooqui N, Shah SA, Iftikhar A, et al. Genetic and
329 antiretroviral drug resistance mutations analysis of reverse transcriptase and protease gene
330 from Pakistani people living with HIV-1. *PLoS One*. 2023;18(8 August).
- 331 27. Abidi SH, Nduva GM, Siddiqui D, Rafaqat W, Mahmood SF, Siddiqui AR, et al.
332 Phylogenetic and Drug-Resistance Analysis of HIV-1 Sequences From an Extensive
333 Paediatric HIV-1 Outbreak in Larkana, Pakistan. *Front Microbiol*. 2021;12.
- 334 28. Cholette F, Joy J, Pelcat Y, Thompson LH, Pilon R, Ho J, et al. HIV-1 phylodynamic
335 analysis among people who inject drugs in Pakistan correlates with trends in illicit opioid
336 trade. *PLoS One*. 2020 Aug 28;15(8):e0237560.
- 337 29. Emmanuel F, Blanchard J, Zaheer HA, Reza T, Holte-Mckenzie M. The HIV/AIDS
338 Surveillance Project mapping approach: An innovative approach for mapping and size
339 estimation for groups at a higher risk of HIV in Pakistan. *AIDS*. 2010;24(SUPPL. 2).
- 340 30. Woods CK, Brumme CJ, Liu TF, Chui CKS, Chu AL, Wynhoven B, et al. Automating
341 HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool. *J*
342 *Clin Microbiol*. 2012;50(6).
- 343 31. Kumar S, Stecher G, Li M, Knyaz C, Tamura K. MEGA X: Molecular evolutionary
344 genetics analysis across computing platforms. *Mol Biol Evol*. 2018;35(6).

- 345 32. Pineda-Peña AC, Faria NR, Imbrechts S, Libin P, Abecasis AB, Deforche K, et al.
346 Automated subtyping of HIV-1 genetic sequences for clinical and surveillance purposes:
347 Performance evaluation of the new REGA version 3 and seven other tools. *Infect Genet*
348 *Evol.* 2013;19.
- 349 33. Struck D, Lawyer G, Ternes AM, Schmit JC, Bercoff DP. COMET: Adaptive context-
350 based modeling for ultrafast HIV-1 subtype identification. *Nucleic Acids Res.*
351 2014;42(18).
- 352 34. Pond SLK, Posada D, Stawiski E, Chappey C, Poon AFY, Hughes G, et al. An
353 evolutionary model-based algorithm for accurate phylogenetic breakpoint mapping and
354 subtype prediction in HIV-1. *PLoS Comput Biol.* 2009;5(11).
- 355 35. Rhee SY, Gonzales MJ, Kantor R, Betts BJ, Ravela J, Shafer RW. Human
356 immunodeficiency virus reverse transcriptase and protease sequence database. *Nucleic*
357 *Acids Res.* 2003;31(1).
- 358 36. Virtanen P, Gommers R, Oliphant TE, Haberland M, Reddy T, Cournapeau D, et al. SciPy
359 1.0: fundamental algorithms for scientific computing in Python. *Nat Methods.* 2020;17(3).
- 360 37. WHO. WHO HIVResNet HIV drug resistance laboratory operational framework, second
361 edition. Geneva: World Health Organization; Licence: CC BY-NC-SA 3.0 IGO; 2020.
- 362 38. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, et al. Drug
363 resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update.
364 *PLoS One.* 2009;4(3).
- 365 39. Bansode V, Drebert ZJ, Travers SAA, Banda E, Molesworth A, Crampin A, et al. Drug
366 resistance mutations in drug-naive HIV type 1 subtype C-infected individuals from rural
367 Malawi. *AIDS Res Hum Retroviruses.* 2011;27(4).

- 368 40. Rhee SY, Tzou PL, Shafer RW. Temporal trends in hiv-1 mutations used for the
369 surveillance of transmitted drug resistance. *Viruses*. 2021;13(5).
- 370 41. Rhee SY, Liu TF, Holmes SP, Shafer RW. HIV-1 subtype B protease and reverse
371 transcriptase amino acid covariation. *PLoS Comput Biol*. 2007;3(5).
- 372 42. Melikian GL, Rhee SY, Taylor J, Fessel WJ, Kaufman D, Towner W, et al. Standardized
373 comparison of the relative impacts of HIV-1 Reverse Transcriptase (RT) mutations on
374 nucleoside RT inhibitor susceptibility. *Antimicrob Agents Chemother*. 2012;56(5).
- 375 43. Li S, Ouyang J, Zhao B, An M, Wang L, Ding H, et al. The S68G polymorphism is a
376 compensatory mutation associated with the drug resistance mutation K65R in CRF01_AE
377 strains. *BMC Infect Dis*. 2020;20(1).
- 378 44. Xu HT, Colby-Germinario SP, Huang W, Oliveira M, Han Y, Quan Y, et al. Role of the
379 K101E substitution in HIV-1 reverse transcriptase in resistance to rilpivirine and other
380 nonnucleoside reverse transcriptase inhibitors. *Antimicrob Agents Chemother*.
381 2013;57(11).
- 382 45. Wang Y, Xing H, Liao L, Wang Z, Su B, Zhao Q, et al. The development of drug
383 resistance mutations K103N Y181C and G190A in long term Nevirapine-containing
384 antiviral therapy. *AIDS Res Ther*. 2014;11(1).
- 385 46. Chin BS, Shin HS, Kim G, Wagner GA, Gianella S, Smith DM. Short communication:
386 Increase of HIV-1 K103N transmitted drug resistance and its association with Efavirenz
387 use in South Korea. *AIDS Res Hum Retroviruses*. 2015;31(6).
- 388 47. Yan L, Yu F, Zhang H, Zhao H, Wang L, Liang Z, et al. Transmitted and acquired hiv-1
389 drug resistance from a family: A case study. *Infect Drug Resist*. 2020;13.

- 390 48. Kuznetsova A, Lebedev A, Gromov K, Kazennova E, Zazzi M, Incardona F, et al.
391 Pre-existing singleton E138A mutations in the reverse transcriptase gene do not affect the
392 efficacy of first-line antiretroviral therapy regimens using rilpivirine in human
393 immunodeficiency virus-infected patients. *Clin Case Rep.* 2022;10(2).
- 394 49. Xu HT, Colby-Germinario SP, Asahchop EL, Oliveira M, McCallum M, Schader SM, et
395 al. Effect of mutations at position E138 in HIV-1 reverse transcriptase and their
396 interactions with the M184I mutation on defining patterns of resistance to nonnucleoside
397 reverse transcriptase inhibitors rilpivirine and etravirine. *Antimicrob Agents Chemother.*
398 2013;57(7).
- 399 50. Liu Y, Zhang Y, Li H, Wang X, Jia L, Han J, et al. Natural presence of the V179D and
400 K103R/V179D mutations associated with resistance to nonnucleoside reverse
401 transcriptase inhibitors in HIV-1 CRF65_cpx strains. *BMC Infect Dis.* 2020;20(1).
- 402 51. Vingerhoets J, Tambuyzer L, Azijn H, Hoogstoel A, Nijs S, Peeters M, et al. Resistance
403 profile of etravirine: Combined analysis of baseline genotypic and phenotypic data from
404 the randomized, controlled Phase III clinical studies. *AIDS.* 2010;24(4).
- 405 52. Stanford University HIV Drug Resistance Database. NNRTI Resistance Notes [Internet].
406 2022 [cited 2023 Sep 4]. Available from: [https://hivdb.stanford.edu/dr-
407 summary/resistance-notes/NNRTI/](https://hivdb.stanford.edu/dr-summary/resistance-notes/NNRTI/)
- 408 53. Basson AE, Rhee SY, Parry CM, El-Khatib Z, Charalambous S, De Oliveira T, et al.
409 Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on
410 susceptibility to newer nonnucleoside reverse transcriptase inhibitors. *Antimicrob Agents
411 Chemother.* 2015;59(2).

- 412 54. NACP. Consolidation Guidelines for the Prevention and Treatment of HIV and AIDS in
413 Pakistan [Internet]. 2020 [cited 2024 Jan 9]. Available from:
414 <https://nacp.gov.pk/howwework/technicalguidelinestac.html>
- 415 55. NACP. Consolidated Guidelines for the Treatment of HIV and AIDS in Pakistan
416 [Internet]. 2015 [cited 2024 Jan 9]. Available from:
417 <https://nacp.gov.pk/howwework/technicalguidelinestac.html>
- 418 56. Mohan A, Shaikh MTA, Wara UU, Rackimuthu S, Costa AC dos S, Lal PM, et al.
419 HIV/AIDS among children in Ratodero, Pakistan amidst the COVID-19 pandemic:
420 Challenges, efforts, and recommendations. *Clin Epidemiol Glob Health*. 2021;12.
- 421 57. WHO. Who. 2019 [cited 2024 Jan 10]. Update of recommendations on first- and second-
422 line antiretroviral regimens. Available from:
423 <https://www.who.int/publications/i/item/WHO-CDS-HIV-19.15>
- 424 58. Emmanuel F, Fatima M. Coverage to curb the emerging HIV epidemic among injecting
425 drug users in Pakistan: Delivering prevention services where most needed. *Int J Drug*
426 *Policy*. 2008;19(SUPPL. 1).
- 427 59. Archibald CP, Shaw SY, Emmanuel F, Otho S, Reza T, Altaf A, et al. Geographical and
428 temporal variation of injection drug users in Pakistan. *Sex Transm Infect*.
429 2013;89(SUPPL. 2).
- 430 60. Emmanuel F, Salim M, Akhtar N, Arshad S, Reza TE. Second-generation surveillance for
431 HIV/AIDS in Pakistan: results from the 4th round of Integrated Behavior and Biological
432 Survey 2011–2012. *Sex Transm Infect*. 2013 Nov;89(Suppl 3):iii23–8.

- 433 61. Khan AA, Awan AB, Qureshi SU, Razaque A, Zafar ST. Large sharing networks and
434 unusual injection practices explain the rapid rise in HIV among IDUs in Sargodha,
435 Pakistan. *Harm Reduct J.* 2009;6.
- 436 62. UNAIDS. UNAIDS DATA 2020 [Internet]. 2020 [cited 2023 Dec 11]. Available from:
437 https://www.unaids.org/sites/default/files/media_asset/2020_aids-data-book_en.pdf